OncoSenX
Business Services · Washington, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
701 5th Ave Ste 4200, Seattle, Washingto...Website
www.oncosenx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About OncoSenX
OncoSenX is a late-stage pre-clinical cancer company based in Seattle, Washington, focused on developing targeted therapies for solid tumors using a unique Proteo-Lipid Vehicle (PLV) and plasmid DNA. Their mission is to create next-generation cancer treatments that are more precise and less invasive, aiming to induce apoptosis in cancerous cells through genetic information. The company targets transcriptionally active cells, particularly those related to p53, and employs a non-toxic delivery system that has shown promising safety profiles in pre-clinical studies. OncoSenX's innovative approach positions it to serve patients seeking advanced cancer therapies with reduced side effects.Explore more
OncoSenX Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OncoSenX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at OncoSenX
Check out if OncoSenX is spiking on competitors!
Funding: Get notified immidiatlly once OncoSenX has new funding data
Click to see if OncoSenX had a recent Job posting/layoffs
OncoSenX, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when OncoSenX launches new products
Check if OncoSenX has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on OncoSenX recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined OncoSenX as Masked Content
Find 2 more new buyers
Compare Similar Companies to OncoSenX
Compare insights from companies similar to OncoSenX, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$6.5M
11-50
Public
$340.5M
2015
KB
Kristi BalacyHead Senior Director, Clinical Development Operations & of Clinical Operations
Company Profile Activity
Activity Insights
OncoSenX is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
OncoSenX is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about OncoSenX.
OncoSenX Tech Stack
A closer look at the technologies used by OncoSenX
OncoSenX News & Media
Seattle biotech startup OncoSenX raising more cash for cancer-fighting therapies
Biotech startup OncoSenX is raising more cash to help support its pipeline of therapeutics that aim to kill cancer cells based on their genetics. Its technology targets solid tumors based on a patented lipid nanoparticle gene delivery system and a highly targeted DNA payload. The Seattle-based company just extended its oversubscribed SAFE (Simple Agreement for Future Equity) to allow for more capital, confirmed CEO Matthew Scholz. It is also planning on raising a $30 millionSeattle biotech startup OncoSenX raises $3M to develop tumor-killing therapeutics
Seattle biotech startup OncoSenX has reeled in $3 million to advance its pipeline of therapeutics that aim to kill cancer cells based on their genetics. OncoSenX’s technology targets solid tumors based on a patented lipid nanoparticle gene delivery system and a highly targeted DNA payload. The company claims that its approach is “a less invasive, more precise intervention” of cancer therapy. OncoSenX is a spinout out of Oisin Biotechnologies, a 5-year-old Seattle company led byOncoSenX Raises $3M in Pre Seed Funding
OncoSenX, Inc., a Seattle, WA-based late preclinical-stage company developing therapeutics to kill cancer cells based on their genetics, raised $3m in pre-seed funding. The backers were not disclosed. The company intends to use the funds to accelerate the preclinical research necessary to begin phase 1 clinical development. Led by Matthew Scholz, chief executive officer, and […] The post OncoSenX Raises $3M in Pre Seed Funding appeared first on FinSMEs.OncoSenX Raises $3 Million to Advance New Class of Cancer Therapeutics
SEATTLE--(BUSINESS WIRE)--OncoSenX, Inc., a late preclinical-stage company developing therapeutics to kill cancer cells based on their genetics, today announced it has raised $3 million in pre-seed funding to advance its pipeline. “These funds will allow us to accelerate the preclinical research necessary for us to begin phase 1 clinical development,” said Matthew Scholz, chief executive officer of OncoSenX. “We believe our non-viral gene therapy for solid tumors represents the first in a new c
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding OncoSenX
Sign Up For FreeTo access detailed company insights
OncoSenX is a late-stage pre-clinical cancer company based in Seattle, Washington, focused on developing targeted therapies for solid tumors using a unique Proteo-Lipid Vehicle (PLV) and plasmid DNA. Their mission is to create next-generation cancer treatments that are more precise and less invasive, aiming to induce apoptosis in cancerous cells th... Read More
